H.C. Wainwright lowered the firm’s price target on Xeris Biopharma to $5.50 from $6 and keeps a Buy rating on the shares post the Q3 report. The firm sees positive 2024 adjusted EBITDA and an “unjustified financing overhang” on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XERS:
